SHILPAMED

** Shares of Shilpa Medicare SHME.NS rise 2.4% at 645 rupees

** SHME on Monday says its unit enters into deal with Switzerland-based mAbTree Biologics for development, manufacture, marketing and sale of a new biological entity

** Stock set to gain for a second session straight

** SHME shares down ~23% so far this year; pharma index .NIPHARM down ~11%

(Reporting by Yagnoseni Das in Bengaluru)

(([email protected];))

March 17 (Reuters) - Shilpa Medicare Ltd SHME.NS:

• SHILPA BIOLOGICALS ENTERED INTO A BINDING TERM SHEET WITH MABTREE BIOLOGICS AG

• TERM SHEET FOR DEVELOPMENT, MANUFACTURE, MARKETING, SALE OF NEW BIOLOGICAL ENTITY

Source text: ID:nBSEbZ3Nz0

Further company coverage: SHME.NS

(([email protected];;))

March 14 (Reuters) - Shilpa Medicare Ltd SHME.NS:

• USFDA INSPECTION AT SHILPA PHARMA UNIT-2 CLOSED WITH ZERO OBSERVATIONS

Source text: ID:nBSE3MDjcb

Further company coverage: SHME.NS

(([email protected];;))

March 7 (Reuters) - Shilpa Medicare Ltd SHME.NS:

• SHILPA MEDICARE LTD - USFDA CONDUCTS INSPECTION AT SHILPA PHARMA UNIT-1

• SHILPA MEDICARE LTD - PHARMA RECEIVES ONE PROCEDURAL OBSERVATION FROM USFDA

Source text: ID:nBSE6XF7ph

Further company coverage: SHME.NS

(([email protected];))

Feb 13 (Reuters) - Shilpa Medicare Ltd SHME.NS:

• SHILPA MEDICARE LTD - RECEIVES CDSCO APPROVAL FOR NOR URSODEOXYCHOLIC ACID TABLETS

• SHILPA MEDICARE LTD - CDSCO RECOMMENDS MARKETING AUTHORIZATION FOR NAFLD TREATMENT

Source text: ID:nBSE1MjXx2

Further company coverage: SHME.NS

(([email protected];))

Jan 23 (Reuters) - Shilpa Medicare Ltd SHME.NS:

• SUBSIDIARY RECEIVED CERTIFICATE OF SUITABILITY FROM EDQM FOR API, TERIFLUNOMIDE

Source text: ID:nBSE24mLds

Further company coverage: SHME.NS

(([email protected];;))

Jan 10 (Reuters) - Shilpa Medicare Ltd SHME.NS:

• GETS EUROPE APPROVAL FOR TADALAFIL ORODISPERIBLE FILMS

Source text: ID:nBSEc1X0WN

Further company coverage: SHME.NS

(([email protected];;))

Dec 20 (Reuters) - Shilpa Medicare Ltd SHME.NS:

• EUROPE GMP CERTIFICATE FOR UNIT VII, NACHARAM, HYDERABAD FROM EMA, AUSTRIA

Source text: ID:nBSE2TbwK6

Further company coverage: SHME.NS

(([email protected];;))

Nov 27 (Reuters) - Shilpa Medicare Ltd SHME.NS:

• USFDA APPROVAL OF NDA IMKELDI FILLED BY PARTNER SHORLA ONCOLOGY

Source text: ID:nBSE8whSvr

Further company coverage: SHME.NS

(([email protected];;))

** Shares of Shilpa Medicare SHME.NS up 3.3% at 891 rupees

** SHME on Monday said its unit received regulatory nod from the European Directorate for the Quality of Medicines & Healthcare for its for its drug Octreotide

** The drug is used to treat severe diarrhea in some tumor patients

** SHME shares up ~ 171% so far this year; pharma index .NIPHARM up 29%

(Reporting by Sethuraman NR)

(([email protected]; (+91 9945291420); Reuters Messaging: [email protected]))

Nov 18 (Reuters) - Shilpa Medicare Ltd SHME.NS:

• SHILPA MEDICARE - RECEIVED CEP FROM EDQM FOR API, OCTREOTIDE

• SHILPA MEDICARE - UNIT GOT CERTIFICATE OF SUITABILITY FROM EDQM

Further company coverage: SHME.NS

(([email protected];))

** Shares of Shilpa Medicare SHME.NS rise 6.7% to 880 rupees, their biggest one-day gain since Oct. 8

** Pharma co's Q2 consol profit and revenue rises over 11-fold and 13%, respectively, helped by traction in its emerging markets and formulation segment

** SHME sees third-busiest day in nearly three months, with over 391,000 shares traded

** Stock extends YTD gains to 166% vs 122% gain in peer Solara Active Pharma SOLA.NS

(Reporting by Aleef Jahan in Bengaluru)

(([email protected]))

Nov 13 (Reuters) - Shilpa Medicare Ltd SHME.NS:

• SEPT-QUARTER CONSOL NET PAT 179.4 MILLION RUPEES

• SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 3.44 BILLION RUPEES

Source text: ID:nBSE2xtgsB

Further company coverage: SHME.NS

(([email protected];;))

Oct 31 (Reuters) - Shilpa Medicare Ltd SHME.NS:

• CONCLUSION OF USFDA INSPECTION OF CO'S UNIT VI IN BENGALURU

• INSPECTION CONCLUDED WITH ISSUANCE OF FORM 483 WITH FOUR OBSERVATIONS

Source text: ID:nBSE2Nl2Pb

Further company coverage: SHME.NS

(([email protected];;))

Oct 16 (Reuters) - Shilpa Medicare Ltd SHME.NS:

• CDMO CUSTOMER RECEIVES FAST-TRACK DESIGNATION FOR ITS INVESTIGATIONAL DRUG CANDIDATE

Source text for Eikon: ID:nBSE190LqL

Further company coverage: SHME.NS

(([email protected];;))

** Shares of Shilpa Medicare SHME.NS rise 2% to 820 rupees

** Pharma co's unit received certificate of suitability from European Directorate for Quality of Medicines and Healthcare (EDQM) for Desmopressin, an active pharma ingredient (API)

** Desmopressin is used to treat central diabetes insipidus and bedwetting

** Stock has surged over two-fold so far this year vs a 37% rise in Nifty pharma index .NIPHARM

(Reporting by Ashna Teresa Britto in Bengaluru)

(([email protected]))

Oct 3 (Reuters) - Shilpa Medicare Ltd SHME.NS:

• UNIT GOT CERTIFICATE OF SUITABILITY FROM EDQM FOR API, DESMOPRESSIN

Source text for Eikon: ID:nBSE8VQFyK

Further company coverage: SHME.NS

(([email protected];;))

** Shares of Shilpa Medicare SHME.NS rise as much as 4.7% to record high of 924 rupees

** Antique Stock Broking starts with a "buy" and TP of 1,300 rupees - a 47% premium over last close

** Brokerage expects SHME's revenue to grow at ~34% CAGR over FY 25-27, driving EBITDA margin to 35% by FY27

** Growth to be driven by active pharmaceutical ingredient launches, robust pipeline of limited-competition products, capacity build-up in higher rev businesses like biosimilars

** SHME has hit 7 record highs in Sept, gaining 17% in the period

** Stock has surged 171% in 2024, set for best year ever

(Reporting by Nishit Navin)

(([email protected];))

Sept 4 (Reuters) - Shilpa Medicare Ltd SHME.NS:

• SHILPA MEDICARE LTD - SUBMISSION OF NDA TO U.S. FDA BY UNICYCIVE

• SHILPA MEDICARE- SUBMISSION OF NDA TO US FDA FOR OXYLANTHANUM CARBONATE

Source text for Eikon: ID:nNSE2SHYNS

Further company coverage: SHME.NS

(([email protected];))

Aug 26 (Reuters) - Shilpa Medicare Ltd SHME.NS:

• SHILPA MEDICARE LTD- SUCCESSFUL OUTCOME OF PHASE 3 STUDIES OF SMLNUD07 - NORUDCA

• SHILPA MEDICARE LTD - TRIAL RESULTED IN SIGNIFICANT, AT LEAST ONE STAGE, DECREASE IN LIVER FIBROSIS

• SHILPA MEDICARE LTD - COMPLETED PHASE-3 CLINICAL STUDIES OF ITS NOVEL PRODUCT SMLNUD07

• SHILPA MEDICARE LTD - THERE WAS A SIGNIFICANT REDUCTION IN FAT ACCUMULATION IN LIVER

• SHILPA MEDICARE LTD - PLANS TO SUBMIT THESE PHASE 3 CLINICAL TRIAL FINDINGS AT EARLIEST TO CDSCO

Source text for Eikon: ID:nBSE8DmCB9

Further company coverage: SHME.NS

(([email protected];))

Aug 7 (Reuters) - Shilpa Medicare Ltd SHME.NS:

• SUCCESSFUL COMPLETION OF PHASE 1 CLINICAL TRIAL FOR RECOMBINANT HUMAN ALBUMIN 20%

Source text for Eikon: ID:nBSE3QX7Wx

Further company coverage: SHME.NS

(([email protected];;))

July 23 (Reuters) - Shilpa Medicare Ltd SHME.NS:

• GOT MARKET APPROVAL FOR ADALIMUMAB 40 MG/0.4 ML SOLUTION FOR INJECTION IN MOROCCO

Source text for Eikon: ID:nBSE2hykn

Further company coverage: SHME.NS

(([email protected];))

July 9 (Reuters) - Shilpa Medicare Ltd SHME.NS:

• UNIT 2, RAICHUR CLEARED ANVISA-BRAZIL GMP INSPECTION

Source text for Eikon: ID:nBSE8GzNp5

Further company coverage: SHME.NS

(([email protected];))

** Shares of Shilpa Medicare SHME.NS rise as much as 15.4%; last up ~11% at 642 rupees, highest since July 2021

** The pharma co says Unicycive Therapeutics UNCY.O reported positive results for SHME's trial of Oxylanthanum Carbonate (OLC) drug

** Drug used for treatment for hyperphosphatemia in chronic kidney disease patients

** UNCY will place purchase order for supply of OLC tablets by June 30, 2025

** Stock eyes busiest trading session since mid-April, volumes over 4.4x the 30-day avg

** Session's gains lift stock to weekly rise of ~12.4%, SHME eyes biggest weekly gain since late-Feb

(Reporting by Manvi Pant in Bengaluru)

(([email protected]; +918447554364;))

June 25 (Reuters) - Shilpa Medicare Ltd SHME.NS:

• USFDA INSPECTION CLOSE OUT OF BIO-ANALYTICAL LABORATORY, UNIT 7, HYDERABAD

• USFDA INSPECTION CLOSED WITH THE ISSUANCE OF ESTABLISHMENT INSPECTION REPORT

• FACILITY IS CLASSIFIED AS NO ACTION INDICATED

Further company coverage: SHME.NS

(([email protected];))

** Shares of Shilpa Medicare Ltd SHME.NS rise as much as 8% to 486.75 rupees

** Stock on track to snap two days of losses

** Pharmaceutical co says, unit filed its first drug master file of recombinant human albumin 20% with U.S. Food and Drug Administration

** Drug Master File is used to provide detailed information about a drug's manufacturing, packaging and storing

** Blood volume loss is treated with recombinant human albumin 20%

** Stock trading above its 200-day simple moving avg since Jan. 31

** More than 280,000 shares traded as of 1:42 p.m. IST, lower than their 30-day moving avg of 311,247 shares

** SHME last up 7.9%, adding to YTD gains of ~47.2%

(Reporting by Meenakshi Maidas in Bengaluru)

(([email protected];))

June 4 (Reuters) - Shilpa Medicare Ltd SHME.NS:

• UNIT FILED DRUG MASTER FILE OF RECOMBINANT HUMAN ALBUMIN 20% WITH USFDA

Source text for Eikon: ID:nBSE4wGkwq

Further company coverage: SHME.NS

(([email protected];;))

** Shares of Shilpa Medicare SHME.NS rise as much as 4.9% to 530 rupees; last up 2%

** Pharma co reports net PAT of 245 mln rupees (about $3 mln) in March quarter, vs a year-ago loss of 80.4 mln rupees

** Revenue from operations up 10.7% Y/Y

** EBITDA margin expands to 25% from 15% a year earlier

** SHME eyes to snap three straight weeks of losses if current trends hold

** Including session's gains, stock up 56.9% YTD

($1 = 83.1625 Indian rupees)

(Reporting by Navamya Ganesh Acharya in Bengaluru)

(([email protected]; +91 8805175330 ;))

May 23 (Reuters) - Shilpa Medicare Ltd SHME.NS:

• MARCH-QUARTER CONSOL NET PAT 245 MILLION RUPEES VERSUS LOSS 80.4 MILLION RUPEES

• MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 2.92 BILLION RUPEES VERSUS 2.64 BILLION RUPEES

Source text for Eikon: [ID:]

Further company coverage: SHME.NS

(([email protected];))

** Shares of Shilpa Medicare SHME.NS rose as much as 3.9%, last up 1.3% at 513.95 rupees

** Pharma co announced completion of clinical trial of SML-007 drug for treatment of non-alcoholic fatty liver disease

** Nifty Pharma index .NIPHARM, which SHME is not part of, is up 0.42%

** YTD, stock up 55.8% compared to 12.4% climb in pharma index

(Reporting by Varun Vyas in Bengaluru)

(([email protected]))